Mergers and acquisitions – Page 9
-
BusinessDaiichi Sankyo awarded damages from former Ranbaxy owners
Arbitration says Singh family withheld information about regulatory investigations during Ranbaxy takeover
-
BusinessAbbot boosts heart devices with St Jude buyout
Medical devices consolidation continues with $25bn deal, but Abbott expresses concerns over proposed Alere merger
-
BusinessCancer deals spread
AbbVie nabs antibody specialist Stemcentrx, while Sanofi pursues Medivation
-
BusinessChemours sheds disinfectants and aniline
Dow Chemical and Germany’s Lanxess will buy plants as Chemours restructures following its spin-off from DuPont
-
BusinessUS treasury rules scupper Pfizer–Allergan merger
Government aims to crack down on corporate tax avoidance through ‘inversion’ deals
-
BusinessRoche sketches out Blueprint collaboration
Drug discovery startup will contribute to cancer immunotherapy projects aimed at kinase enzymes
-
BusinessSanofi and Merck & Co end vaccines partnership
Two-decade-long alliance will split by end of 2016
-
BusinessAkzoNobel to buy BASF’s industrial coatings
€475 million deal includes technology, products and sites in the UK and South Africa
-
BusinessMylan to buy Meda in further generics consolidation
£6.9bn deal will give combined company ‘critical mass’ in US market
-
BusinessChemChina offers to buy Syngenta in $43bn takeover
Directors welcome deal that will allow agrochemicals giant to establish a presence in China
-
BusinessMedical devices consolidation continues
Abbott to buy Alere for $5.8bn to augment its point-of-care diagnostics business
-
BusinessShire bets big on rare diseases
$32bn Baxalta buyout will deepen Shire’s commitment to developing specialist drugs for small patient populations
-
Business
ChemChina buys German machinery maker
Plastics and rubber equipment manufacturer KraussMaffei Group will retain German headquarters after €1bn deal
-
Business
ThermoFisher will buy Affymetrix to expand genetic testing
Deal boosts Thermo’s position in growing genomics field as well as adding antibodies and assay technology
-
Business
GSK’s ViiV to buy HIV drugs from BMS
Deal hands over Bristol-Myers Squibb’s entire HIV pipeline as the company looks to quit virology research
-
Business
AstraZeneca to buy Acerta for blood cancer drug
Deal will strengthen AstraZeneca’s immunotherapy offering
-
-
Business
BioAtla and Pfizer to collaborate on antibody research
Two-way agreement to share technology and royalties on new cancer drugs
-
-
BusinessDow and DuPont mega-merger heralds break-up of giants
New firm will split itself in speciality, agrichemical and materials businesses with R&D taking a hit from cost savings